These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 18670644

  • 1. Hypoxia-specific drug tirapazamine does not abrogate hypoxic tumor cells in combination therapy with irinotecan and methylselenocysteine in well-differentiated human head and neck squamous cell carcinoma a253 xenografts.
    Bhattacharya A, Tóth K, Durrani FA, Cao S, Slocum HK, Chintala S, Rustum YM.
    Neoplasia; 2008 Aug; 10(8):857-65. PubMed ID: 18670644
    [Abstract] [Full Text] [Related]

  • 2. Lack of microvessels in well-differentiated regions of human head and neck squamous cell carcinoma A253 associated with functional magnetic resonance imaging detectable hypoxia, limited drug delivery, and resistance to irinotecan therapy.
    Bhattacharya A, Tóth K, Mazurchuk R, Spernyak JA, Slocum HK, Pendyala L, Azrak R, Cao S, Durrani FA, Rustum YM.
    Clin Cancer Res; 2004 Dec 01; 10(23):8005-17. PubMed ID: 15585636
    [Abstract] [Full Text] [Related]

  • 3. Irinotecan pharmacokinetic and pharmacogenomic alterations induced by methylselenocysteine in human head and neck xenograft tumors.
    Azrak RG, Yu J, Pendyala L, Smith PF, Cao S, Li X, Shannon WD, Durrani FA, McLeod HL, Rustum YM.
    Mol Cancer Ther; 2005 May 01; 4(5):843-54. PubMed ID: 15897249
    [Abstract] [Full Text] [Related]

  • 4. Se-methylselenocysteine sensitizes hypoxic tumor cells to irinotecan by targeting hypoxia-inducible factor 1alpha.
    Chintala S, Tóth K, Cao S, Durrani FA, Vaughan MM, Jensen RL, Rustum YM.
    Cancer Chemother Pharmacol; 2010 Oct 01; 66(5):899-911. PubMed ID: 20066420
    [Abstract] [Full Text] [Related]

  • 5. Selective modulation of the therapeutic efficacy of anticancer drugs by selenium containing compounds against human tumor xenografts.
    Cao S, Durrani FA, Rustum YM.
    Clin Cancer Res; 2004 Apr 01; 10(7):2561-9. PubMed ID: 15073137
    [Abstract] [Full Text] [Related]

  • 6. Potentiation of irinotecan sensitivity by Se-methylselenocysteine in an in vivo tumor model is associated with downregulation of cyclooxygenase-2, inducible nitric oxide synthase, and hypoxia-inducible factor 1alpha expression, resulting in reduced angiogenesis.
    Yin MB, Li ZR, Tóth K, Cao S, Durrani FA, Hapke G, Bhattacharya A, Azrak RG, Frank C, Rustum YM.
    Oncogene; 2006 Apr 20; 25(17):2509-19. PubMed ID: 16518418
    [Abstract] [Full Text] [Related]

  • 7. Efficacy of increasing the therapeutic index of irinotecan, plasma and tissue selenium concentrations is methylselenocysteine dose dependent.
    Azrak RG, Cao S, Pendyala L, Durrani FA, Fakih M, Combs GF, Prey J, Smith PF, Rustum YM.
    Biochem Pharmacol; 2007 May 01; 73(9):1280-7. PubMed ID: 17239826
    [Abstract] [Full Text] [Related]

  • 8. Tumor vascular maturation and improved drug delivery induced by methylselenocysteine leads to therapeutic synergy with anticancer drugs.
    Bhattacharya A, Seshadri M, Oven SD, Tóth K, Vaughan MM, Rustum YM.
    Clin Cancer Res; 2008 Jun 15; 14(12):3926-32. PubMed ID: 18559614
    [Abstract] [Full Text] [Related]

  • 9. Overexpression of Bax enhances antitumor activity of chemotherapeutic agents in human head and neck squamous cell carcinoma.
    Guo B, Cao S, Tóth K, Azrak RG, Rustum YM.
    Clin Cancer Res; 2000 Feb 15; 6(2):718-24. PubMed ID: 10690558
    [Abstract] [Full Text] [Related]

  • 10. Synergistic antitumor activity of capecitabine in combination with irinotecan.
    Cao S, Durrani FA, Rustum YM.
    Clin Colorectal Cancer; 2005 Jan 15; 4(5):336-43. PubMed ID: 15663838
    [Abstract] [Full Text] [Related]

  • 11. Selenium protects against toxicity induced by anticancer drugs and augments antitumor activity: a highly selective, new, and novel approach for the treatment of solid tumors.
    Fakih M, Cao S, Durrani FA, Rustum YM.
    Clin Colorectal Cancer; 2005 Jul 15; 5(2):132-5. PubMed ID: 16098255
    [Abstract] [Full Text] [Related]

  • 12. Augmented therapeutic efficacy of irinotecan is associated with enhanced drug accumulation.
    Azrak RG, Cao S, Durrani FA, Toth K, Bhattacharya A, Rustum YM.
    Cancer Lett; 2011 Dec 08; 311(2):219-29. PubMed ID: 21872389
    [Abstract] [Full Text] [Related]

  • 13. Therapeutic synergy between irinotecan and 5-fluorouracil against human tumor xenografts.
    Azrak RG, Cao S, Slocum HK, Tóth K, Durrani FA, Yin MB, Pendyala L, Zhang W, McLeod HL, Rustum YM.
    Clin Cancer Res; 2004 Feb 01; 10(3):1121-9. PubMed ID: 14871992
    [Abstract] [Full Text] [Related]

  • 14. Usefulness of combined treatment with mild temperature hyperthermia and/or tirapazamine in the treatment of solid tumors: its independence of p53 status.
    Masunaga S, Ono K, Takahashi A, Ohnishi K, Ohnishi T, Suzuki M, Nagata K, Kinashi Y, Nagasawa H, Uto Y, Hori H.
    Cancer Sci; 2003 Jan 01; 94(1):125-33. PubMed ID: 12708486
    [Abstract] [Full Text] [Related]

  • 15. Inhibition of colon cancer growth by methylselenocysteine-induced angiogenic chemomodulation is influenced by histologic characteristics of the tumor.
    Bhattacharya A, Tóth K, Sen A, Seshadri M, Cao S, Durrani FA, Faber E, Repasky EA, Rustum YM.
    Clin Colorectal Cancer; 2009 Jul 01; 8(3):155-62. PubMed ID: 19632930
    [Abstract] [Full Text] [Related]

  • 16. Se-methylselenocysteine offers selective protection against toxicity and potentiates the antitumour activity of anticancer drugs in preclinical animal models.
    Cao S, Durrani FA, Tóth K, Rustum YM.
    Br J Cancer; 2014 Apr 02; 110(7):1733-43. PubMed ID: 24619073
    [Abstract] [Full Text] [Related]

  • 17. Combination of the antivascular agent ZD6126 with hypoxic cytotoxin treatment, with reference to the effect on quiescent tumor cells and the dependency on p53 status of tumor cells.
    Masunaga S, Nagasawa H, Uto Y, Hori H, Ohnishi K, Takahashi A, Ohnishi T, Suzuki M, Nagata K, Kinashi Y, Ono K.
    Oncol Rep; 2005 Aug 02; 14(2):393-400. PubMed ID: 16012721
    [Abstract] [Full Text] [Related]

  • 18. Phase I study of weekly CPT-11 (irinotecan)/docetaxel in patients with advanced solid tumors.
    Font A, Sanchez JM, Rosell R, Taron M, Martinez E, Guillot M, Manzano JL, Margeli M, Barnadas A, Abad A.
    Lung Cancer; 2002 Aug 02; 37(2):213-8. PubMed ID: 12140145
    [Abstract] [Full Text] [Related]

  • 19. DNA damage measured by the comet assay in head and neck cancer patients treated with tirapazamine.
    Dorie MJ, Kovacs MS, Gabalski EC, Adam M, Le QT, Bloch DA, Pinto HA, Terris DJ, Brown JM.
    Neoplasia; 1999 Nov 02; 1(5):461-7. PubMed ID: 10933062
    [Abstract] [Full Text] [Related]

  • 20. 4-[3-(2-Nitro-1-imidazolyl)propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive agent as radiosensitizer in vitro and in vivo: comparison with tirapazamine.
    Papadopoulou MV, Ji M, Rao MK, Bloomer WD.
    Oncol Res; 2001 Nov 02; 12(8):325-33. PubMed ID: 11589303
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.